Clinical Report: Intravenous Immunoglobulin as an Adjunct Therapy for Sepsis
Overview
This study evaluates the efficacy and safety of intravenous immunoglobulin (IVIG) as an adjunct therapy in elderly patients with sepsis. Results indicate that IVIG significantly reduces 28-day mortality and improves organ function compared to conventional therapy alone.
Background
Sepsis is a leading cause of mortality, particularly in older adults who are more susceptible due to age-related immunosenescence. Conventional treatments often fail to adequately address the dysregulated immune response in sepsis.
Data Highlights
Outcome
IVIG Group
Control Group
P-value
28-day mortality
18.3%
31.7%
0.043
SOFA score reduction (day 7)
3.7 ± 1.2
2.1 ± 1.0
< 0.001
CRP levels (mg/L)
55.6 ± 10.4
38.3 ± 9.7
< 0.001
PCT levels (ng/mL)
5.3 ± 1.6
3.1 ± 1.4
< 0.001
ICU stay (days)
9.8 ± 2.7
12.4 ± 3.1
0.024
Duration of mechanical ventilation (days)
4.2 ± 1.1
5.7 ± 1.4
0.011
Key Findings
IVIG reduced 28-day mortality from 31.7% to 18.3% (p = 0.043).
SOFA scores improved more rapidly in the IVIG group (mean reduction of 3.7 vs. 2.1 points, p < 0.001).
CRP levels decreased significantly more in the IVIG group (55.6 mg/L vs. 38.3 mg/L, p < 0.001).
PCT levels were also lower in the IVIG group (5.3 ng/mL vs. 3.1 ng/mL, p < 0.001).
ICU length of stay was shorter in the IVIG group (9.8 days vs. 12.4 days, p = 0.024).
Duration of mechanical ventilation was reduced in the IVIG group (4.2 days vs. 5.7 days, p = 0.011).
Clinical Implications
Further studies are needed to confirm these results in larger populations.
Conclusion
Adjunctive IVIG therapy in elderly sepsis patients is associated with improved clinical outcomes.
